News

The Dose Podcast: Ep 1 "TB and the AMR Crisis"

The Stop TB Partnership's Working Group on New Drugs presents a new podcast series entitled "The Dose". In this series, the WGND will bring together drug developers, researchers in the TB R&D field, TB patients, global health experts, and donors to discuss, prioritize, and develop strategies to help meet the most pressing needs faced by the TB drug R&D community.

Episode 1 "TB and the AMR Crisis"

Episode 1 will focus on TB and antimicrobial resistance (AMR). Today, AMR is one of the defining health issues of our time. Drug resistant tuberculosis is the cornerstone of the global AMR challenge, which accounts for a quarter of AMR fatalities per year. This podcast will highlight the opportunities, and challenges to advancing action on AMR and tuberculosis.

Moderator: Shobha Shukla, Citizen News Service

Speaker: Mario Raviglione, University of Milan (Previously Global TB Programme, WHO) 

Speaker: Manica Balasegaram, Global Antibiotic Research and Develpment Partnership (GARDP)

 

Listen on Soundcloud: https://soundcloud.com/user-87209407/the-dose-podcast-july-2018 

More News
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...